Emmanuel J Favaloro/LinkedIn
Nov 15, 2025, 15:41
Emmanuel J. Favaloro: Transitioning Patients from DOACs to Heparin
Emmanuel J Favaloro, Editor in Chief of Seminars in Thrombosis and Hemostasis, shared a post on LinkedIn:
“Transitioning of Patients from Direct-Acting Oral Anticoagulant to Heparin: Impact on Laboratory Testing. This Commentary has just been released online, and is free to download from.”
Title: Transitioning of Patients from Direct-Acting Oral Anticoagulant to Heparin: Impact on Laboratory Testing
Authors: Deepa J. Arachchillage, Saravanan Vinayagam, Annie Parsons, Nilanthi Karawitage, Mike Laffan
Read the full article here.
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy